• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies for symptomatic hyponatremia

byBrian DoughertyandAlex Chan
November 6, 2020
in Emergency, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There is no difference in overcorrection rate when using slow continuous infusion or rapid intermittent bolus administration of hypertonic saline to correct hyponatremia.

2. Use of a rapid intermittent bolus strategy is associated with a lower incidence of requiring relowering therapy and with an increased incidence of achieving target correction rate within one hour.

Evidence Rating Level: 1 (Excellent)

The most common electrolyte imbalance encountered in clinical practice, hyponatremia, is often treated effectively with hypertonic saline. Both under- and over-correction, however, are associated with toxicity. Correction with small, fixed boluses is recommended by recent guidelines due to perceived efficacy, safety, and ease of administration. There is a paucity of data, however, clarifying whether hypertonic saline is best administered via slow continuous infusion (SCI) or by rapid intermittent bolus (RIB). This randomized controlled trial compared 87 patients managed with RIB (mean [SD] age = 72.9 [12.4] years, 48.3% male) with 91 patients managed with SCI (mean [SD] age = 73.2 [12.1] years, 41.8% male). The primary outcome was the incidence of overcorrection of hyponatremia. Mean serum sodium in both the RIB and SCI cohorts was 118.2 mmol/L. It was found that overcorrection occurred in 15 patients in the RIB cohort and 22 patients in the SCI cohort (absolute risk difference -6.9, 95% CI -18.8 to 4.9, p = 0.26). The RIB cohort, however, showed a lower incidence of requiring relowering treatment than the SCI cohort (41.4% vs. 57.1%, absolute risk difference -15.8%, 95% CI -30.3% to -1.3%, p = .04). This translates to a number needed to treat of 6.3. Furthermore, patients in the RIB cohort, on average, reached target correction rate within one hour more frequently than did patients in the SCI cohort (32.2% vs. 17.6%, absolute risk difference 14.6%, 95% CI 2% to 27.2%, p = 0.02) This translates to a number needed to treat of 6.8. In all, this study showed that correction of hyponatremia with both RBI and SCI is safe and effective with no difference in overcorrection rate, though RBI may be the preferred strategy due to a lower incidence of requiring relowering therapy and higher incidence of achieving target correction rate within one hour.

Click to read the study in JAMA Internal Medicine

Image: PD

RELATED REPORTS

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

Nerandomilast slows FVC decline in progressive pulmonary fibrosis

AAV gene therapy shows durable benefit in hemophilia B

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hyponatremiainternal medicine
Previous Post

Impact of COVID-19 on care of hospitalized newborns

Next Post

Healthcare workers in patient facing roles at 3 times greater risk of COVID-19 hospital admissions

RelatedReports

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Pharma

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

July 11, 2025
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Pharma

Nerandomilast slows FVC decline in progressive pulmonary fibrosis

July 8, 2025
Primary thromboembolism prophylaxis may be effective in advanced cancer
Hematology

AAV gene therapy shows durable benefit in hemophilia B

July 7, 2025
Chronic Disease

Frailty scores alone may be poor predictors of intensive care admission or hospital stay duration

June 16, 2025
Next Post
AAP supports mandatory influenza vaccination of health care providers

Healthcare workers in patient facing roles at 3 times greater risk of COVID-19 hospital admissions

Using HEART score to risk stratify patients with chest pain is safe but underutilized in the ED

Factors associated with poor clinical outcomes of STEMI after door-to-balloon time target achieved

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Adjuvant radiotherapy does not improve survival following prostatectomy in men with localized or locally advanced prostate cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • MLC901 may be effective in treatment of post-concussion symptoms in phase III study
  • Risk of dementia increased with gabapentin prescription in back pain patients
  • New-generation antiseizure medications are better tolerated for patients with epilepsy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.